American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography

被引:1846
作者
Saslow, Debbie [1 ]
Boetes, Carla
Burke, Wylie
Harms, Steven
Leach, Martin O.
Lehman, Constance D.
Morris, Elizabeth
Pisano, Etta
Schnall, Mitchell
Sener, Stephen
Smith, Robert A.
Warner, Ellen
Yaffe, Martin
Andrews, Kimberly S.
Russell, Christy A.
机构
[1] Amer Canc Soc, Canc Control Sci Dept, Atlanta, GA 30329 USA
[2] Univ Med Ctr Nijmegen, Dept Radiol, Nijmegen, Netherlands
[3] Univ Washington, Seattle, WA 98195 USA
[4] Breast Ctr NW Arkansas, Fayetteville, AR USA
[5] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[6] Inst Canc Res, UK Clin Magnet Resonance Res Grp, Sect Magnet Resonance, Surrey, England
[7] Royal Marsden NHS Fdn Trust, Surrey, England
[8] Univ Washington, Med Ctr, Sect Head Breast Imaging, Seattle, WA 98195 USA
[9] Seattle Canc Care Alliance, Seattle, WA USA
[10] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[11] Univ N Carolina, UNC Sch Med, UNC Biomed Res Imaging Ctr, Chapel Hill, NC USA
[12] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[13] Evanston Northwestern Hlth Care, Dept Surg, Evanston, IL USA
[14] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[15] Amer Canc Soc, Canc Control Sci Dept, Atlanta, GA 30329 USA
[16] Univ Toronto, Dept Med, Toronto, ON, Canada
[17] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[18] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada
[19] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada
[20] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA
[21] Univ So Calif, Norris Breast Ctr, Los Angeles, CA USA
关键词
HIGH FAMILIAL RISK; CONTRAST-ENHANCED MRI; PARENCHYMAL PATTERNS; SUSCEPTIBILITY GENE; DIAGNOSTIC-ACCURACY; COST-EFFECTIVENESS; MUTATION CARRIERS; PREDICTION MODEL; HODGKINS-DISEASE; YOUNG-WOMEN;
D O I
10.3322/canjclin.57.2.75
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New evidence on breast Magnetic Resonance Imaging (MRI) screening has become available since the American Cancer Society (ACS) last issued guidelines for the early detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed new recommendations for women at different defined levels of risk. Screening MR1 is recommended for women with an approximately 20-25% or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin disease. There are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mammography. Diagnostic uses of MRI were not considered to be within the scope of this review.
引用
收藏
页码:75 / 89
页数:15
相关论文
共 81 条
  • [1] Aisenberg AC, 1997, CANCER, V79, P1203, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO
  • [2] 2-2
  • [3] Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme
    Amir, E
    Evans, DG
    Shenton, A
    Lalloo, F
    Moran, A
    Boggis, C
    Wilson, M
    Howell, A
    [J]. JOURNAL OF MEDICAL GENETICS, 2003, 40 (11): : 807 - 814
  • [4] Anderson J, 2004, BREAST CANCER RES TR, V88, pS188
  • [5] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [6] The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    Antoniou, AC
    Pharoah, PPD
    Smith, P
    Easton, DF
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1580 - 1590
  • [7] Premalignant and in situ breast disease: Biology and clinical implications
    Arpino, G
    Laucirica, R
    Elledge, RM
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (06) : 446 - 457
  • [8] Prospective breast cancer risk prediction model for women undergoing screening mammography
    Barlow, William E.
    White, Emily
    Ballard-Barbash, Rachel
    Vacek, Pamela M.
    Titus-Ernstoff, Linda
    Carney, Patricia A.
    Tice, Jeffrey A.
    Buist, Diana S. M.
    Geller, Berta M.
    Rosenberg, Robert
    Yankaskas, Bonnie C.
    Kerlikowske, Karla
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (17): : 1204 - 1214
  • [9] Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility:: Recommendation statement
    Berg, AO
    Allan, JD
    Calonge, N
    Frame, PS
    Gordis, L
    Gregory, KD
    Harris, R
    Johnson, MS
    Klein, JD
    Loveland-Cherry, C
    Moyer, VA
    Ockene, JK
    Petitti, DB
    Siu, AL
    Teutsch, SM
    Yawn, BP
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (05) : 355 - 361
  • [10] Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer
    Berg, WA
    Gutierrez, L
    NessAiver, MS
    Carter, WB
    Bhargavan, M
    Lewis, RS
    Ioffe, OB
    [J]. RADIOLOGY, 2004, 233 (03) : 830 - 849